Andere Sprachen Pliant Therapeutics, Inc.

Aktien

A2P4YV

US7291391057

PLRX

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 26.04.2024			% 5 Tage	% 1. Jan.
11.81 ^USD	-0.59%		-5.67%	-34.79%

12.03.	Pliant Therapeutics, Inc. kündigt beschleunigten Entwicklungsplan für Bexotegrast zur Behandlung der idiopathischen Lungenfibrose an	CI
05.03.	PLIANT THERAPEUTICS, INC. : RBC Capital Markets bekräftigt seine Kaufempfehlung	ZM

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Pliant Therapeutics to Participate in Upcoming Investor Events	02.04.
Pliant Therapeutics Announces Upcoming Presentations at the 2024 American Thoracic Society International Conference	27.03.
Nimbus Therapeutics Appoints Katharine Knobil, M.D., to Board of Directors	13.03.
Pliant Therapeutics, Inc. Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis	12.03.
Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis	12.03.
Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis	12.03.
Pliant Therapeutics : March 2024 Corporate Presentation	29.02.
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2023 Financial Results	27.02.
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2023 Financial Results	27.02.
Pliant Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	27.02.
Pliant Therapeutics to Participate in Upcoming Investor Conferences	26.02.
Pliant Therapeutics to Participate in Upcoming Investor Conferences	26.02.
Pliant Therapeutics to Participate in Upcoming Investor Events	07.02.
Pliant Therapeutics to Participate in Upcoming Investor Events	07.02.
Pliant Therapeutics Reports Interim 'Positive' Safety, Efficacy Data for Potential Liver Disease Drug	05.02.
Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis	04.02.
Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis	04.02.
Pliant Therapeutics, Inc. Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis	04.02.
Pliant Therapeutics Insider Sold Shares Worth $443,173, According to a Recent SEC Filing	19.01.
Top Premarket Decliners	11.01.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Pliant Therapeutics, Inc.

Aktien

A2P4YV

US7291391057

PLRX

Andere Sprachen

Filter